Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Displaying entries 2476 - 2500 of 3913 in total
Main Class Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass ▼ Formula
Neutral glycosphingolipids GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AF01
  • Galbeta1-4GlcNAcbeta1-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44260524 1591.882142 C74H133N3O33
Neutral glycosphingolipids GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AM01
  • GalNAcbeta1-3Galalpha1-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44260580 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AL01
  • Galbeta1-3GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44260700 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504BR01
  • Galbeta1-4GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
  • VI3(Galb 1-4GlcNAcb )-Lc4Cer(d18:1/16:0)
44260948 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AL01
  • Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
  • nLc6Cer(d18:1/16:0)
44261060 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BG01
  • Galbeta1-3GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44261228 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CB01
  • Galalpha1-3Galbeta1-4GlcNAcbeta1-3(GalNAcbeta1-4)Galbeta1-4Glcbeta-Cer(d18:1/16:0)
  • IV3Gala -nLc4Cer(d18:1/16:0)
44261396 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CF01
  • Galbeta1-4GlcNAcalpha1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44261428 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505EJ01
  • Galbeta1-4GlcNAcbeta1-3(Galbeta1-4GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44261804 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505EL01
  • GalNAcbeta1-3Galalpha1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/16:0)
  • IV 3-nLcOse4(d18:1/16:0)
44261812 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AK01
  • GalNAcbeta1-3Galalpha1-3(Galbeta1-4GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44261892 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AM01
  • Galalpha1-3(GalNAcbeta1-4Galbeta1-4GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44261908 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BH01
  • Galbeta1-4GlcNAcbeta1-3Galalpha1-3(GalNAcbeta1-4)Galbeta1-4Glcbeta-Cer(d18:1/16:0)
44261684 1591.882142 C74H133N3O33
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AI03
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • type IV H(d18:1/20:0)
44260230 1590.923278 C76H138N2O32
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BM03
  • Fucalpha2-3Galbeta1-3GalNAcbeta1-4Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260470 1590.923278 C76H138N2O32
Neutral glycosphingolipids GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AK03
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260566 1590.923278 C76H138N2O32
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AE03
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • type I B antigen(d18:1/20:0)
44260646 1590.923278 C76H138N2O32
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AE03
  • Galalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • type II B antigen(d18:1/20:0)
44261006 1590.923278 C76H138N2O32
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CV03
  • Gala 1-3Lex(d18:1/20:0)
  • Galalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44261550 1590.923278 C76H138N2O32
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AW03
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44261614 1590.923278 C76H138N2O32
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BB03
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44261638 1590.923278 C76H138N2O32
Acidic glycosphingolipids Gangliosides LMSP0601BY03
  • NeuGcalpha2-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44262366 1589.902877 C75H135N3O32
Acidic glycosphingolipids Gangliosides LMSP0601CJ03
  • Galbeta1-3GalNAcbeta1-4(NeuGcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44262438 1589.902877 C75H135N3O32
Acidic glycosphingolipids Gangliosides LMSP0601FF03
  • NeuGcalpha2-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44262982 1589.902877 C75H135N3O32
Acidic glycosphingolipids Gangliosides LMSP0601DD05
  • KDNalpha2-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44262584 1588.944013 C77H140N2O31

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.0.0

Last updated: August 19, 2024